Guggenheim lowers ArriVent BioPharma stock price target to $28 By Investing.com
Guggenheim has reduced its price target for ArriVent BioPharma (NASDAQ:AVBP) to $28 from $30, while maintaining a Buy rating. This adjustment follows the company's Q3 2026 results, which included a Phase 3 miss for FURVENT and new Phase 1 data for CDH17 ADC ARR-217. Despite the setback, ArriVent ended the quarter with a strong cash position and continues to advance other clinical trials.
Guggenheim lowers ArriVent BioPharma stock price target to $28 By Investing.com
Guggenheim has reduced its price target for ArriVent BioPharma (NASDAQ:AVBP) to $28 from $30, while maintaining a Buy rating. This adjustment follows the company's Q3 2026 results, which included a Phase 3 trial miss for FURVENT and new Phase 1 data for CDH17 ADC ARR-217. Despite the setback, ArriVent BioPharma holds a strong balance sheet with $393.2 million in cash and investments.
Precision Trading with Arrivent Biopharma Inc. (AVBP) Risk Zones
This report from Stock Traders Daily provides a detailed analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—complete with entry, target, and stop loss levels. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for various time horizons.
Truist Securities maintains ArriVent BioPharma at Buy, raises price target to $24 from $21
Truist Securities has reiterated its "Buy" rating for ArriVent BioPharma and increased its price target from $21 to $24, representing a 14.3% jump. This new target implies a potential upside of 69.5% from the closing price of $14.16 on November 9. Other analysts have also recently issued "Buy" ratings with price targets ranging from $29 to $30.
ArriVent BioPharma, Inc. (AVBP) Tops Q3 EPS by 23c
ArriVent BioPharma, Inc. (AVBP) announced its Q3 earnings, reporting an EPS of ($0.81), which surpassed analyst estimates by $0.23. Analysts had predicted an EPS of ($1.04) for the quarter. This positive surprise indicates stronger performance than expected.
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma reported its third-quarter 2026 financial results, highlighting continued enrollment in its pivotal Phase 3 ALPACCA study for EGFR PACC-mutant NSCLC and encouraging Phase 1 data for its CDH17-targeted ADC, ARR-217. The company also initiated a U.S. Phase 1a/1b study for ARR-002, a dual-target ADC, and strengthened its clinical leadership. Despite the firmonertinib (FURVENT) study not meeting its primary endpoint, the company's cash and investments of $393.2 million are expected to fund operations to mid-2028.
Precision Trading with Arrivent Biopharma Inc. (AVBP) Risk Zones
This article provides a detailed analysis of Arrivent Biopharma Inc. (AVBP) through AI-generated trading strategies and multi-timeframe signal analysis. It identifies weak near and mid-term sentiment but a strong long-term outlook, along with specific entry, target, and stop-loss levels for position, momentum, and risk hedging strategies. The analysis highlights elevated downside risk due to a lack of long-term support signals.
ArriVent BioPharma, Inc. (AVBP) Investigation: Bronstein, Gewirtz
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ArriVent BioPharma, Inc. (NASDAQ:AVBP) after the company's global Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint, leading to a significant stock price decline. The investigation focuses on whether ArriVent adequately disclosed information regarding the trial's progress and the timing of negative efficacy data. Investors who purchased ArriVent securities are encouraged to contact the firm to learn more and assist the investigation.
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
Aarvik Therapeutics announced a significant milestone achievement, provided a partnership update, and is set to present information on its MUTTA™ and AQUALINK™ platforms at the 17th Annual WADC Conference. The announcement was made via a PR release distributed by Quantisnow, highlighting developments for the health care company.
ArriVent BioPharma, Inc. (AVBP) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for ArriVent BioPharma, Inc. (AVBP). It displays the average monthly price return for the stock from 2024 to 2026, alongside current trading data. The article also provides navigation to other financial information like news, statistics, and historical data for AVBP.
ArriVent BioPharma | SCHEDULE 13G/A: Others
This article indicates a Schedule 13G/A filing for ArriVent BioPharma, which typically signals a significant ownership stake in the company by an institutional investor or group. The "Others" designation suggests the filing is not from a traditional insider or a 5% beneficial owner who might file a 13D. These filings are important for tracking institutional interest and potential shifts in control.
ArriVent BioPharma, Inc. (AVBP) Seasonal returns chart - Yahoo Finance
The Yahoo Finance article provides a seasonality chart for ArriVent BioPharma, Inc. (AVBP), showing average monthly price returns from 2024 to 2026. As of November 2nd, AVBP's stock price was 13.35 USD, experiencing a decline of 10.22% during regular trading hours. The article also lists various market indices and cryptocurrency prices.
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $30
Guggenheim has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) but has adjusted its target price downwards to $30. This indicates a continued positive outlook on the company's prospects despite a revised valuation.
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
ArriVent BioPharma presented promising Phase I data for its CDH17-targeting antibody-drug conjugate, ARR-217, in heavily pretreated metastatic colorectal cancer patients. The study showed anti-tumor activity, with a 44.8% objective response rate and a 93.1% disease-control rate at the 6 mg/kg dose. The company plans further dose optimization and potential later-stage development, with initial Phase Ib monotherapy data expected in the first half of 2027.
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $29
BTIG has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its target price at $29. This indicates continued confidence in the company's prospects from the investment firm.
ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial
ArriVent BioPharma announced strong results for its experimental lung cancer drug, firmonertinib, showing a 68% tumor response rate and a median progression-free survival of 16 months at a higher dose. These findings, published in Cancer Cell, support the ongoing Phase 3 ALPACCA trial for patients with EGFR PACC mutations, an uncommon form of non-small cell lung cancer with limited treatment options. The drug also demonstrated activity against brain metastases and showed superior activity compared to an existing therapy in lab studies.
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside
ArriVent BioPharma, Inc.'s average 12-month price target has been increased from $22.91 to $24 by 11 analysts, with forecasts ranging from $15 to $30 per share. This updated target suggests a potential upside of approximately 14% based on the Oct. 23 closing price. The consensus rating remains a "Buy" from all 12 covering analysts.
Form 8K Arrivent Biopharma Inc For: 26 October By Investing.com
Arrivent Biopharma Inc. has filed a Form 8K for October 26, 2026. The article notes that the company's stock symbol AVBP is down 25.52%. The content primarily consists of the filing announcement and various market data.
Form 8-K ArriVent BioPharma, Inc. For: Oct 25
ArriVent BioPharma, Inc. filed a Form 8-K on October 26, 2026, detailing an event from October 25, 2026. The report announced initial Phase 1 data for their cadherin-17 (CDH17)-targeted antibody-drug conjugate ARR-217 (MRG007) in patients with gastrointestinal cancers, presented at the European Society for Medical Oncology Congress 2026. This information was included as Exhibit 99.1, a press release, to the filing.
ArriVent BioPharma Reports 44.8% Objective Response Rate for ARR-217 in Late-Line Colorectal Cancer Patients
ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, an antibody-drug conjugate targeting cadherin-17, in late-line colorectal cancer patients. The study showed a 44.8% objective response rate and a 93.1% disease control rate at a 6 mg/kg dose, with a generally manageable safety profile. ArriVent plans to advance ARR-217 into a Phase 1b dose optimization study, with further data expected in 2027.
At one dose, an experimental cancer drug had a 44.8% response rate after earlier colorectal cancer treatments.
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate (ADC) ARR-217, showing a 44.8% objective response rate in heavily pretreated colorectal cancer patients at a 6 mg/kg dose. The drug also demonstrated a 93.1% disease control rate and was generally well-tolerated, with most adverse events being Grade 1/2. These positive results support advancing ARR-217 into Phase 1b dose optimization studies, with further data expected in 2027.
ArriVent BioPharma, Inc. Estimates – NASDAQ:AVBP
This article provides an overview of ArriVent BioPharma, Inc. (NASDAQ:AVBP) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The page emphasizes that the information is not investment advice and encourages users to conduct their own research.
ArriVent to present phase 1 data for ARR-217 at ESMO
ArriVent BioPharma, Inc. will present initial safety and efficacy data from its Phase 1 study of ARR-217 at the European Society for Medical Oncology Congress 2026. ARR-217 is a CDH17-directed antibody-drug conjugate being developed for patients with locally advanced or metastatic solid tumors, particularly gastrointestinal cancers. The company acquired global rights to ARR-217 (also known as MRG007) from Lepu Biopharma Co., Ltd., and plans a webinar to discuss the data.
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 47.3% Share Drop
Kirby McInerney LLP is investigating Arrivent BioPharma (NASDAQ: AVBP) after its shares dropped by 47.3% following the announcement that its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint. The law firm is looking into potential violations of federal securities laws or other unlawful business practices by Arrivent or its senior management. Investors who purchased Arrivent securities are encouraged to contact the firm to discuss their rights.
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 47.3% Share Drop
Kirby McInerney LLP is investigating Arrivent BioPharma (NASDAQ: AVBP) after its shares dropped 47.3% following the announcement that its Phase 3 FURVENT trial for firmonertinib did not meet its primary endpoint. The trial, for treating EGFR exon 20 insertion-mutant non-small cell lung cancer, showed no meaningful improvement in progression-free survival over chemotherapy. Investors are encouraged to contact the law firm for more information regarding their potential rights.
ArriVent’s Firmonertinib Phase 1b Data Published in Cancer Cell
ArriVent BioPharma's Phase 1b trial data for firmonertinib, targeting EGFR PACC mutations in non-small cell lung cancer, has been published in Cancer Cell. The publication highlights firmonertinib's efficacy in a patient population historically difficult to treat with standard EGFR inhibitors. This significant publication suggests ArriVent may use these results to advance firmonertinib into a registrational trial, particularly given its FDA Breakthrough Therapy Designation and Orphan Drug Designation.
ArriVent Advances Cancer Drug Pipeline With First U.S. Trial
ArriVent BioPharma has initiated its first U.S. Phase 1 clinical trial for ARR-002, an antibody-drug conjugate targeting ovarian and endometrial cancers. This dual-target treatment, which recognizes MUC16 and NaPi2b, aims to overcome limitations of single-target therapies by addressing varying protein expressions in tumors. The trial expands ArriVent's oncology development into gynecologic cancers, complementing existing programs.
A lung cancer drug showed a 68% response rate at the higher dose. No targeted standard exists for this mutation.
ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in EGFR PACC-mutant non-small cell lung cancer, showing promising response rates and progression-free survival, particularly at higher doses and in patients with brain metastases. This drug aims to address a significant unmet medical need for a patient population currently lacking a targeted standard of care. The company is continuing enrollment in its global Phase 3 ALPACCA trial for firmonertinib.
Press Release Distribution & Media Outreach Platform for PR Agencies
Bronstein, Gewirtz & Grossman, LLC is investigating ArriVent BioPharma, Inc. (NASDAQ:AVBP) after its global Phase 3 FURVENT trial failed to meet its primary endpoint. The investigation centers on whether ArriVent adequately disclosed information regarding the trial's progress and the timing of negative efficacy data, which led to a significant 50%-63% drop in the company's stock price. Investors who purchased ArriVent securities are encouraged to contact the firm to learn more about the investigation.
Press Release Distribution & Media Outreach Platform for PR Agencies
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ArriVent BioPharma, Inc. (AVBP) following a significant stock price decline. This decline occurred after the company announced its Phase 3 FURVENT trial failed to meet its primary endpoint, raising questions about the adequacy of its disclosures to investors. The law firm encourages investors who purchased ArriVent securities to join the investigation.
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint
ArriVent BioPharma announced that its experimental lung cancer drug, firmonertinib, failed to meet the primary endpoint of progression-free survival in a pivotal Phase 3 trial for non-small cell lung cancer with EGFR exon 20 insertion mutations. While secondary endpoints showed some clinical benefit, the failure to significantly improve progression-free survival compared to chemotherapy raises questions about its development as a first-line treatment. The company is currently reviewing the full data set to determine the drug's future.
ArriVent BioPharma, Inc. (AVBP) Options Chain
This article provides the options chain data for ArriVent BioPharma, Inc. (AVBP) for the expiration date of January 15, 2027. It lists various call and put options, including their strike prices, last trade dates and times, last prices, and other relevant option metrics. The data is delayed by 15 minutes and covers both in-the-money call and put options.
ArriVent doses first patient with ARR-002 dual-target ADC for ovarian cancer
ArriVent BioPharma has dosed its first U.S. patient in a Phase 1 trial for ARR-002, a novel tetravalent antibody-drug conjugate (ADC) designed to treat advanced or metastatic ovarian and endometrial cancers. This ADC uniquely targets two antigens, MUC16 and NaPi2b, simultaneously, a departure from most approved ADCs that target a single antigen. The trial aims to establish the maximum tolerated dose and evaluate the drug's safety and efficacy, given its distinct dual-target mechanism.
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $27
H.C. Wainwright has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and maintained its price target of $27. This continued positive outlook suggests the firm sees strong potential in the biopharma company's future performance.
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has launched a securities investigation into ArriVent BioPharma (AVBP) after its shares plummeted by 50% to 63% on October 6, 2026. This significant drop occurred because the company's lead candidate, firmonertinib, failed to meet its primary endpoint in the pivotal Phase 3 FURVENT trial for non-small-cell lung cancer. The firm is encouraging AVBP investors who suffered losses to submit their information to assess potential legal rights.
ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors
Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (NASDAQ: AVBP) after its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint, leading to a significant drop in share price. The law firm encourages investors who purchased Arrivent securities to contact them to learn about their rights regarding potential federal securities law violations.
A cancer drug targets two proteins in ovarian and endometrial tumors. Its first patient has been dosed.
ArriVent BioPharma announced that it has dosed the first patient in its U.S. Phase 1 trial of ARR-002, a novel antibody-drug conjugate (ADC) targeting MUC16 and NaPi2b for ovarian and endometrial cancer. This marks the company's second ADC to enter clinical testing, expanding its pipeline beyond lung and gastrointestinal cancers. ArriVent retains all rights to ARR-002 outside of Greater China, where it has an exclusive licensing agreement with Shanghai Allist Pharmaceuticals.
ArriVent BioPharma Doses First Patient in Phase 1 U.S. Trial of ARR-002 for Ovarian and Endometrial Cancer
ArriVent BioPharma has dosed its first patient in a U.S. Phase 1 clinical trial for ARR-002, a dual-target tetravalent antibody-drug conjugate designed for ovarian and endometrial cancer. This therapy targets MUC16 and NaPi2b proteins, aiming to improve drug delivery and efficacy. The company also announced an exclusive licensing agreement with Shanghai Allist Pharmaceuticals for ARR-002's development and commercialization in Greater China.
Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
This article highlights bullish sentiments from analysts on three healthcare companies: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX), and Rocket Pharmaceuticals (RCKT). Analysts reiterated Buy ratings for all three, with specific price targets and upside potentials mentioned for each. The report details the analysts' credentials and the consensus ratings for the stocks.
ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history
This article provides a detailed financial overview of ArriVent BioPharma, Inc. (AVBP), including its current stock price, recent performance data, and key financial metrics. It also outlines the company's business activities, focusing on its clinical-stage drug development for cancer treatments, particularly firmonertinib for non-small cell lung cancer. The report includes analyst insights, earnings trends, and valuation measures for AVBP.
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into ArriVent BioPharma, Inc. (NASDAQ: AVBP) following a significant stock drop. The investigation stems from ArriVent's announcement on October 6, 2026, that its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint. SBS is inviting investors who suffered losses of $100,000 or more to participate in the fraud investigation.
Shanghai Allist Drops 20% On US Partner ArriVent’s Failed Trial
Shares of Shanghai Allist Pharmaceuticals Co. dropped 20% after its US partner ArriVent Biopharma Inc. announced the failure of its late-stage lung cancer drug, firmonertinib, in a global Phase 3 trial. This failure effectively eliminated the drug's global commercial prospects for previously untreated non-small cell lung cancer patients. The sharp decline was the maximum allowed on Shanghai’s STAR Market and the biggest since Allist's 2020 listing.
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into ArriVent BioPharma, Inc. (AVBP) on behalf of investors who suffered losses of $100,000 or more. The investigation follows ArriVent's announcement that its global Phase 3 FURVENT trial failed to meet its primary endpoint, causing a sharp decline in stock value. SBS is examining whether the company made false or misleading statements to investors.
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
Levi & Korsinsky, LLP has initiated an investigation into ArriVent BioPharma (AVBP) following a significant stock price drop on October 6, 2026. This decline occurred after the company announced that its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint, just five months after a $250 million stock offering. The investigation focuses on potential securities law violations and whether ArriVent made misleading statements to investors.
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside
ArriVent BioPharma, Inc.'s average 12-month price target has been lowered from $42.45 to $37.55 by 11 analysts, with forecasts ranging from $18 to $50 per share. This new target suggests a potential upside of approximately 32% from its Oct. 5 closing price. The consensus rating among 12 analysts remains a "Buy."
ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma's stock dropped 46% after its non-small cell lung cancer (NSCLC) candidate, firmonertinib, failed to meet its primary endpoint in a Phase III trial. The FURVENT trial did not show a meaningful improvement in progression-free survival over chemotherapy, leading to a significant stock price decline despite some positive secondary endpoint trends. This setback follows recent positive news from Johnson & Johnson for a competing treatment in the same patient population.
ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint
ArriVent BioPharma's Phase 3 FURVENT trial for firmonertinib in first-line EGFR exon 20 insertion NSCLC failed to meet its primary endpoint of progression-free survival by blinded independent central review. Despite this setback, the trial showed secondary clinical benefits and a manageable safety profile, leading the company to reassess its development strategy. An analyst maintains a Buy rating on AVBP with a $45 price target, while TipRanks' AI Analyst, Spark, rates it Neutral due to financial fundamentals and technical indicators.
Why Is ArriVent BioPharma Stock Tumbling Today? - ArriVent BioPharma (NASDAQ:AVBP)
ArriVent BioPharma (NASDAQ: AVBP) stock significantly dropped after its Phase 3 FURVENT trial for the lung cancer drug firmonertinib failed to meet its primary endpoint of progression-free survival. Despite this, the drug showed clinical benefits in secondary endpoints, including improved progression-free survival by investigator assessment and a strong objective response rate. The safety profile was consistent with previous studies, but the primary endpoint miss led to a substantial stock decline.
ArriVent collapses on disappointing lung cancer data
ArriVent BioPharma's experimental lung cancer treatment, furmonertinib, failed to meet its primary goal in a late-stage study, causing the company's shares to drop over 50%. The drug, intended as a first-line therapy for EGFR exon 20 insertion mutation lung cancer, did not significantly delay tumor progression compared to chemotherapy. This setback impacts ArriVent's ability to compete in the market for this rare genetic alteration, a target also pursued by companies like Johnson & Johnson, AstraZeneca, and Taiho Oncology.
ArriVent BioPharma, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ArriVent BioPharma, Inc. (AVBP)
Levi & Korsinsky has initiated an investigation into ArriVent BioPharma, Inc. (AVBP) regarding potential violations of federal securities laws. This follows a significant stock drop on October 6, 2026, after the company announced its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint, leading to a 50%-63% share collapse. The investigation will examine whether the company adequately disclosed the trial's progress and negative efficacy data prior to the announcement, especially given previous statements about not planning an interim analysis.